VIDEO: Rise in glucose with drug therapy for thyroid eye disease ‘easily controlled’
ATLANTA — In this video exclusive, Terry Smith, MD, discusses results of an analysis of clinical trial data on blood glucose effects associated with teprotumumab therapy for thyroid eye disease.
Smith is the Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences and professor of internal medicine at the University of Michigan Medical School.
Teprotumumab (Tepezza, Horizon Therapeutics) was approved by the FDA in 2020 for the treatment of adults with thyroid eye disease. About 10% of adults prescribed the drug develop hyperglycemia, most of them patients with pre-existing diabetes or carbohydrate intolerance, according to Smith. These increases in glucose level can be managed with the patient’s regular diabetes medications or therapies for carbohydrate intolerance, Smith said.
Collapse
Read more about